Michael King
Stock Analyst at EF Hutton
(0.90)
# 3,985
Out of 5,147 analysts
107
Total ratings
37.17%
Success rate
-10.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $20.21 | +3,116.23% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $2.82 | +290.07% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.37 | +2,235.77% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.38 | +4,863.77% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $12.04 | +1,561.82% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.60 | +1,282.87% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $781.67 | +10.28% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $44.06 | -45.53% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $3.33 | +4,884.98% | 8 | Mar 28, 2023 | |
| XNCR Xencor | Reiterates: Buy | $42 | $12.77 | +228.90% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $332.92 | -8.69% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $13.78 | +741.80% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.65 | +82.30% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $44.27 | -45.79% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $55.05 | -16.44% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $30.23 | +217.57% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.53 | +6,714.31% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $38.85 | -20.21% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $766.92 | -95.31% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $20.21
Upside: +3,116.23%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $2.82
Upside: +290.07%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.37
Upside: +2,235.77%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.38
Upside: +4,863.77%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $12.04
Upside: +1,561.82%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.60
Upside: +1,282.87%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $781.67
Upside: +10.28%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $44.06
Upside: -45.53%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.33
Upside: +4,884.98%
Xencor
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $12.77
Upside: +228.90%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $332.92
Upside: -8.69%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $13.78
Upside: +741.80%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $5.65
Upside: +82.30%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $44.27
Upside: -45.79%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $55.05
Upside: -16.44%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $30.23
Upside: +217.57%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.53
Upside: +6,714.31%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $38.85
Upside: -20.21%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $766.92
Upside: -95.31%